| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3819476 | La Presse Médicale | 2015 | 7 Pages |
Abstract
SummaryPatients with ANCA-associated vasculitis (AAV) have an increased risk of premature death and organ failure. Treatment strategies with immune-suppressive drugs need to balance disease control and prevention of relapse against the risk of side effects in particular infection and malignancy. The longer-term outcome of patients with AAV who participated in several randomised controlled trials has been published in recent years. The results of these and other newer studies will be the focus of this review.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Oliver Flossmann,